spacer
home > ict > autumn 2018 > quality upkeep
PUBLICATIONS
International Clinical Trials

Quality Upkeep

To ensure a smooth transition from the pre-authorisation to the post-authorisation phase of the lifecycle of a medicinal product, the marketing authorisation (MA) applicant is responsible for ensuring a robust pharmacovigilance (PV) system is in place to monitor patient safety once the product is on the market. During clinical trials, patient exposure is limited and closely monitored, and very specific criteria must be met for patients who are eligible to take part in the study. However, once the product is on the market and more widely available, patient exposure will be much more widespread and patients may experience adverse reactions (ARs) that have not been observed previously in a clinical trial setting.

To maintain compliance with EU post-marketing regulatory requirements, the MA holder (MAH) must ensure that the following are in place:

• PV systems (including appropriate technology, quality management system, and PV processes)
• Qualified Person for PV (QPPV) and deputy and local safety-responsible representatives (where required under national legislation)
• PV system master file (PSMF)
• Risk management and minimisation systems
• Signal management • Global literature search strategy
• EudraVigilance (EV) maintenance, including Article 57 database

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
David Hukin is the Head of Pharmacovigilance and the PV team at Quanticate. David has a PhD in cell physiology and biophysics and 15 years’ experience in the pharmaceutical industry, with more than 14 years working in the PV sector. He has worked across speciality pharma/biotechnology companies and has gained preand post-marketing experience in a range of therapeutic areas, including gastroenterology, hepatology, neurology, oncology, psychiatric conditions, ATMPs, and orphan drug indication products for rare diseases. Since 2015, David has worked in the specialist PV service provider sector, leading multiple large teams responsible for clinical and post-marketing for customers ranging from small pharma/ biotech to large speciality and generic companies, before joining Quanticate in 2018.
spacer
David Hukin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Peli BioThermal showcase CoolPall™ Flex and industry leading solutions at Temperature Control and Logistics Conference

Peli BioThermal, the global name in temperature-controlled packaging, is exhibiting its industry leading shipper systems, including its innovative CoolPall™ Flex, at the 19th Annual Cool Chain Temperature Control and Logistics conference.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement